Full Press Release Details
Inc. Reports Full Year 2024 Financial Results
LAKE CITY, March 27, 2025- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform
for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December
Year 2024 Financial Results:
| Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. Grant revenue totaled $3.1 million while product revenue totaled $0.8 million | ||
| Operating expenses of $43.0 million decreased by 5.2% from the prior year due to higher expenses in 2023 related to platform development and regulatory submission preparation | ||
| Operating loss of $40.1 million compared to operating loss of $42.7 million in 2023 | ||
| Net loss of $37.6 million, compared to net loss of $35.3 million in the prior year, representing a loss of $1.24 per fully diluted share, compared to a loss of $1.20 per fully diluted share in the prior year | ||
| Adjusted EBITDA loss of $33.5 million | ||
| Cash, cash equivalents, and marketable securities of $29.7 million as of December 31, 2024 |
Year 2024 and Recent Business Highlights:
| Inaugurated CoSara Diagnostics Pvt. Ltd.'s oligonucleotide synthesis facility in India to manufacture the Company's patented Co-Primers chemistry | ||
| Attended a number of trade shows and expos throughout 2024, including UHCA/UCAL Fall Convention & Expo, Medlab Africa in Cape Town, and MEDICA Trade Fair in Germany | ||
| Inaugurated a new manufacturing facility in South Salt Lake to manufacture our patented Co-Primers oligonucleotides, the Co-Dx PCR Pro instrument, and test cups for the new Co-Dx PCR platform | ||
| Advanced regulatory strategy through completion of an initial 510(k) application to the U.S. Food and Drug Administration (FDA) for the Co-Dx PCR Pro Platform, which has subsequently been withdrawn with the intention of submitting an enhanced version of the test and instrument for 510(k) clearance |
are pleased by the progress of our pipeline development in 2024," said Dwight Egan, Co-Diagnostics' Chief Executive Officer.
"We recently announced our decision to withdraw our 510(k) application for the Co-Dx PCR Pro and Co-Dx PCR COVID-19
test from the FDA, as we now prepare to gather updated clinical data in support of a new submission for an enhanced version of the test
and instrument. We firmly believe that this decision will allow us to offer an even better test upon our initial launch and streamline
the associated operational and manufacturing processes, which will be leveraged for future commercialization plans across our development
pipeline. Elsewhere, we have made great progress on our tuberculosis test and anticipate clinical evaluations for this indication,
as well as for the HPV multiplex and upper respiratory multiplex tests, all to commence later this year. We remain well positioned
to execute our development and regulatory goals in 2025 and strongly believe in the potential of the platform, our people, and the company
to make a positive impact on the state of global health."
are pleased with how our progress in 2024 has moved us closer to commercializing the new platform, and are now actively
focused on achieving our 2025 goals. As we advance our diagnostic test pipeline, we are committed to generating operational efficiencies
to help offset development costs. We look forward to updating you on our further progress throughout the year," said Brian Brown,
Co-Diagnostics' Chief Financial Officer.
will host a conference call and webcast at 4:30 p.m. EDT today to discuss its financial results with analysts and institutional investors.
The conference call and webcast will be available via:
ir.codiagnostics.com on the Events & Webcasts page
Call: 844-481-2661 (domestic) or 412-317-0652 (international)
call will be recorded and later made available on the Company's website: https://codiagnostics.com.
Co-Dx PCR platform (including the PCR Home , PCR Pro , mobile app, and all associated tests) is subject to review by the
FDA and/or other regulatory bodies and is not yet available for sale.
Co-Diagnostics, Inc.:
Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies.
The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules
(DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform
and to identify genetic markers for use in applications other than infectious disease.
press release contains adjusted EBITDA, which is a non-GAAP measure defined as net income excluding depreciation, amortization, income
tax (benefit) expense, net interest (income) expense, stock-based compensation, change in fair value of contingent consideration,
and realized gain on investments. The Company believes that adjusted EBITDA provides useful information to management and investors
relating to its results of operations. The Company's management uses this non-GAAP measure to compare the Company's performance
to that of prior periods for trend analyses, and for budgeting and planning purposes. The Company believes that the use of adjusted EBITDA
provides an additional tool for investors to use in evaluating ongoing operating results and trends and in comparing the Company's
financial measures with other companies, many of which present similar non-GAAP financial measures to investors, and that it allows for
greater transparency with respect to key metrics used by management in its financial and operational decision-making.
does not consider the non-GAAP measure in isolation or as an alternative to financial measures determined in accordance with GAAP. The
principal limitation of the non-GAAP financial measure is that it excludes significant expenses that are required by GAAP to be recorded
in the Company's financial statements. In order to compensate for these limitations, management presents the non-GAAP financial
measure together with GAAP results. Non-GAAP measures should be considered in addition to results prepared in accordance with GAAP, but
should not be considered a substitute for, or superior to, GAAP results. A reconciliation table of the net income, the most comparable
GAAP financial measure to adjusted EBITDA, is included at the end of this release. The Company urges investors to review the reconciliation
and not to rely on any single financial measure to evaluate the company's business.
press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes,"
"expects," "estimates," "intends," "may," "plans," "will" and
similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist
at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include
statements (i) that our decision to withdraw our 510(k) application for the PCR Pro and associated COVID-19 test from the FDA and gather
updated clinical will allow us to offer an even better test upon our initial launch and streamline the associated operational and manufacturing
processes, and (ii) that we anticipate clinical evaluations for our tuberculosis test, as well as for the HPV multiplex and upper
respiratory multiplex tests to commence later this year. Forward-looking statements are subject to inherent uncertainties, risks
and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements.
Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. There can be no assurance
that any of the anticipated results will occur on a timely basis or at all due to certain risks and uncertainties, a discussion of which
can be found in our Risk Factors disclosure in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC)
on March 27, 2025, and in our other filings with the SEC. The Company does not undertake any obligation to update any forward-looking
statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
of Investor Relations
CO-DIAGNOSTICS, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| December 31, 2024 | December 31, 2023 | |||||||
| Assets | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 2,936,544 | $ | 14,916,878 | ||||
| Marketable investment securities | 26,811,098 | 43,631,510 | ||||||
| Accounts receivable, net | 132,570 | 303,926 | ||||||
| Inventory, net | 1,072,724 | 1,664,725 | ||||||
| Income taxes receivable | - | 26,955 | ||||||
| Prepaid expenses and other current assets | 1,338,762 | 1,597,114 | ||||||
| Total current assets | 32,291,698 | 62,141,108 | ||||||
| Property and equipment, net | 2,761,280 | 3,035,729 | ||||||
| Operating lease right-of-use asset | 2,114,876 | 2,966,774 | ||||||
| Intangible assets, net | 26,101,000 | 26,403,667 | ||||||
| Investment in joint venture | 731,065 | 773,382 | ||||||
| Total assets | $ | 63,999,919 | $ | 95,320,660 | ||||
| Liabilities and stockholders' equity | ||||||||
| Current liabilities | ||||||||
| Accounts payable | $ | 3,294,254 | $ | 1,482,109 | ||||
| Accrued expenses | 2,562,169 | 2,172,959 | ||||||
| Operating lease liability, current | 915,619 | 838,387 | ||||||
| Contingent consideration liabilities, current | 502,819 | 891,666 | ||||||
| Deferred revenue | 40,857 | 362,449 | ||||||
| Total current liabilities | 7,315,718 | 5,747,570 | ||||||
| Long-term liabilities | ||||||||
| Income taxes payable | 713,643 | 659,186 | ||||||
| Operating lease liability | 1,236,560 | 2,152,180 | ||||||
| Contingent consideration liabilities | 422,080 | 748,109 | ||||||
| Total long-term liabilities | 2,372,283 | 3,559,475 | ||||||
| Total liabilities | 9,688,001 | 9,307,045 | ||||||
| Commitments and contingencies (Note 12) | ||||||||
| Stockholders' equity | ||||||||
| Convertible preferred stock, $0.001 par value; 5,000,000 shares authorized; 0 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively | - | - | ||||||
| Common stock, $0.001 par value; 100,000,000 shares authorized; 37,902,222 shares issued and 33,053,544 shares outstanding as of December 31, 2024 and 36,108,346 shares issued and 31,259,668 shares outstanding as of December 31, 2023 | 37,902 | 36,108 | ||||||
| Treasury stock, at cost; 4,848,678 shares held as of December 31, 2024 and December 31, 2023, respectively | (15,575,795 | ) | (15,575,795 | ) | ||||
| Additional paid-in capital | 102,472,210 | 96,808,436 | ||||||
| Accumulated other comprehensive income | 418,443 | 146,700 | ||||||
| Accumulated earnings (deficit) | (33,040,842 | ) | 4,598,166 | |||||
| Total stockholders' equity | 54,311,918 | 86,013,615 | ||||||
| Total liabilities and stockholders' equity | $ | 63,999,919 | $ | 95,320,660 |
INC. AND SUBSIDIARIES
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
| Years Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Product revenue | $ | 770,048 | $ | 991,473 | ||||
| Grant revenue | 3,145,112 | 5,820,565 | ||||||
| Total revenue | 3,915,160 | 6,812,038 | ||||||
| Cost of revenue | 999,124 | 4,184,949 | ||||||
| Gross profit | 2,916,036 | 2,627,089 | ||||||
| Operating expenses | ||||||||
| Sales and marketing | 4,483,339 | 6,860,815 | ||||||
| General and administrative | 16,157,152 | 14,279,441 | ||||||
| Research and development | 20,979,589 | 22,962,593 | ||||||
| Depreciation and amortization | 1,377,266 | 1,230,474 | ||||||
| Total operating expenses | 42,997,346 | 45,333,323 | ||||||
| Loss from operations | (40,081,310 | ) | (42,706,234 | ) | ||||
| Other income, net | ||||||||
| Interest income, net | 1,091,825 | 1,161,913 | ||||||
| Realized gain on investments | 870,745 | 2,243,059 | ||||||
| Gain (loss) on disposition of assets | 8,291 | (2,578 | ) | |||||
| Gain on remeasurement of acquisition contingencies | 714,876 | 1,092,581 | ||||||
| Gain (loss) on equity method investment in joint venture | (186,067 | ) | 100,703 | |||||
| Total other income, net | 2,499,670 | 4,595,678 | ||||||
| Loss before income taxes | (37,581,640 | ) | (38,110,556 | ) | ||||
| Income tax provision (benefit) | 57,368 | (2,777,691 | ) | |||||
| Net loss | $ | (37,639,008 | ) | $ | (35,332,865 | ) | ||
| Other comprehensive loss | ||||||||
| Change in net unrealized gains on marketable securities, net of tax | 271,743 | (146,440 | ) | |||||
| Total other comprehensive income (loss) | $ | 271,743 | $ | (146,440 | ) | |||
| Comprehensive loss | $ | (37,367,265 | ) | $ | (35,479,305 | ) | ||
| Loss per common share: | ||||||||
| Basic and Diluted | $ | (1.24 | ) | $ | (1.20 | ) | ||
| Weighted average shares outstanding: | ||||||||
| Basic and Diluted | 30,335,350 | 29,346,599 |
CO-DIAGNOSTICS, INC. AND SUBSIDIARIES
GAAP AND NON-GAAP MEASURES
of net loss to adjusted EBITDA:
| Years Ended December 31, | ||||||||
| 2024 | 2023 | |||||||
| Net loss | $ | (37,639,008 | ) | $ | (35,332,865 | ) | ||
| Interest income, net | (1,091,825 | ) | (1,161,913 | ) | ||||
| Realized gain on investments | (870,745 | ) | (2,243,059 | ) | ||||
| Depreciation and amortization | 1,377,266 | 1,230,474 | ||||||
| (Gain) loss on disposition of assets | (8,291 | ) | 2,578 | |||||
| Change in fair value of contingent consideration | (714,876 | ) | (1,092,581 | ) | ||||
| Stock-based compensation expense | 5,434,904 | 8,336,856 | ||||||
| Income tax provision (benefit) | 57,368 | (2,777,691 | ) | |||||
| Adjusted EBITDA | $ | (33,455,207 | ) | $ | (33,038,201 | ) |